Ipilimumab vs Rivaroxaban
Ipilimumab vs Rivaroxaban: Overview
This comparison examines the pharmacological differences between Ipilimumab and Rivaroxaban.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Rivaroxaban: Direct Factor Xa inhibitor.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Rivaroxaban β 5-9 hours.
Chemical Properties
Molecular Formula: Rivaroxaban β C19H18ClN3O5S.
Molecular Weight: Rivaroxaban β 435.8820 g/mol.
Type: Ipilimumab β Antibody; Rivaroxaban β Small molecule.